linjc16/ctgov huggingface dataset:
Improving the Diagnostic of Tuberculosis

Study Overview
=================
Brief Summary
-----------------
The presence of M. tuberculosis in non-invasive throat swabs of patients withdrawn for suspected tuberculosis. Hypothesis 10% of patients infected by M. tuberculosis are carrier of M. tuberculosis pharyngeal. Secondary Measure the time to diagnosis of pulmonary TB by comparing the sample versus noninvasive pharyngeal samples taken routinely. Evaluation of the direct cost of the diagnosis of M. tuberculosis by comparing the sample versus noninvasive pharyngeal samples taken routinely. Beijing genotype prevalence among patients with pulmonary tuberculosis.

Official Title
-----------------
Improving the Diagnostic of Tuberculosis

Conditions
-----------------
Tuberculosis

Intervention / Treatment
-----------------
* Biological: Pharyngeal swab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient taken for microbiological examinations kit mycobacterium Patient Major (> 18 years). Patient who freely signed the informed written consent. Patient affiliated to a system of social security. Exclusion criteria Patient minor (<18 years). Patient pregnant or nursing. Major Patient under guardianship. Private Patient liberty or under court order. Patient refusing to sign the informed consent form.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: diagnosis of M.tuberculosis infection<br> | Biological: Pharyngeal swab<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients with microbiological diagnosis of M. tuberculosis infection |  | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pulmonary tuberculosis diagnostic time. |  | 3years | 
| Prevalence of diagnosed patients Beijing |  | 3 years | 
| Direct cost of microbiological diagnosis of extra Beijing genotype | (compared to the cost of the kit TB), reported the percentage of patients diagnosed Beijing. | 3 years |
Endoscopic Ultrasound Evaluation of the Common Bile Duct in Patients With Obstructive Jaundice Due to Bilio-pancreatic Malignancies (ECCO Trial)

Study Overview
=================
Brief Summary
-----------------
To assess the size of the common bile duct in a large cohort of patients with jaundice following a malignant tumor of the head of the pancreas or the distal bile duct receiving a diagnostic EA for biopsy and / or for evaluation of tissue resectability.

Official Title
-----------------
Endoscopic Ultrasound Evaluation of the Common Bile Duct in Patients With Obstructive Jaundice Due to Bilio-pancreatic Malignancies: a Multicenter Prospective Study (ECCO Trial)

Conditions
-----------------
Obstructive Jaundice, Bilio-pancreatic Tumor

Intervention / Treatment
-----------------
* Procedure: Ultrasound endoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with jaundice and an injury to the head of the pancreas recommended for EUS-guided tissue acquisition or staging Patients with jaundice and distal CBD lesion suggestive of cholangiocarcinoma or Vater's ampulla carcinoma recommended for EUS-guided tissue acquisition or staging Serum bilirubin level ≥ 3 mg / dl Age ≥ 18 years old Subject affiliated or beneficiary of a social security scheme. Subject having been informed of this study and having given his no objection Exclusion Criteria: Presence of altered anatomy due to previous gastric surgery (Billroth II or Roux-en-Y anastomosis) Sphincterotomy performed previously, plastic biliary stent or metal stent placement Percutaneous drainage of the bile ducts performed previously Pregnant, breastfeeding or parturient woman Protected patients: Adults under guardianship, curatorship or other legal protection, deprived of their liberty by judicial or administrative decision; hospitalized without consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patient with jaundice<br> | Procedure: Ultrasound endoscopy<br>* After identification of the lesion, the common bile duct will be identified and followed by the point of dilation due to the compression of the known lesion up to the hilum of the liver<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the common bile duct size |  | 1 day |
Effects of a Vitality Dietary Supplement on Physical and Mental Function in Middle-aged Adults

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine the effects of 8 weeks Vitality Product supplementation on physical and mental function in middle-aged adults

Official Title
-----------------
Effects of a Proprietary Ginseng, Cordyceps, and Pomegranate Supplement on Physical and Mental Function in Middle-aged Adults: a Double-blind, Randomized, Placebo-controlled Trial

Conditions
-----------------
Health-related Quality of Life

Intervention / Treatment
-----------------
* Dietary Supplement: Vitality Product
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females aged 40-70 years Signed Informed Consent BMI between 19 and 30 kg/m2 Normotensive, defined as systolic blood pressure 90-140 mmHg and diastolic blood pressure 50-90 mmHg Exclusion Criteria: Regular dietary supplement use and unwilling to discontinue use at least 1 month prior to enrollment in the study Self-reported chronic condition that may affect subject safety (e.g. diabetes, cardiovascular disease) or significantly impact product effectiveness (e.g. chronic fatigue) Pregnancy/suspected pregnancy, breastfeeding Antihypertensive medication use Allergies to any supplement ingredients Consumption of more than 600mg caffeine from any source per day Consumption of energy drinks (e.g. Red Bull, Monster) or any herbal supplement known to affect energy levels Known iron anemia Medically treated for insomnia Medically treated for depression Taking medications known to affect energy, e.g. thyroid medication Tobacco user Planned surgical procedure in next 2 months Participating in another clinical (medical or nutritional) study or likely to enroll in another medical or nutritional study

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Vitality product<br>Proprietary blend of ginseng, cordyceps, and pomegranate | Dietary Supplement: Vitality Product<br>* Proprietary blend of ginseng, cordyceps, and pomegranate taken twice a day for 8 weeks<br>|
| Placebo Comparator: Placebo<br>Placebo | Dietary Supplement: Placebo<br>* Placebo taken twice a day for 8 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Health-related quality of life |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Medical Outcomes Study (MOS) Sexual Function questionnaire |  | 8 weeks | 
| Adverse events |  | 8 weeks |
Thymic Stromal Lymphopoietin (TSLP) in Vitiligo

Study Overview
=================
Brief Summary
-----------------
study & verify the hypothesis of the involvement of TSLP in the pathogenesis of vitiligo in comparison to their levels in the healthy control persons.

Official Title
-----------------
Study of the Cutaneous Expression of Thymic Stromal Lymphopoietin (TSLP) in a Sample of Vitiligo Patients

Conditions
-----------------
Vitiligo

Intervention / Treatment
-----------------
* Other: skin biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Patients with generalized non-segmental vitiligo. Both sexes. Age < 18 years old age. New cases or cases not receiving any medication for at least 3 months ago. Exclusion Criteria: • Age: Patients < 18 years. Segmental or universal vitiligo. Pregnant and lactating females. Autoimmune diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: vitiligo patients<br> | Other: skin biopsy<br>* Lesional skin biopsy was taken from every patient. Also a skin biopsy was taken from every control subject<br>|
| Experimental: controls<br> | Other: skin biopsy<br>* Lesional skin biopsy was taken from every patient. Also a skin biopsy was taken from every control subject<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Expression levels of TSLP in patients of Vitiligo. |  | 7 months |
Reconstruction Technology to Auxiliary Diagnosis and Guarantee Patient Privacy

Study Overview
=================
Brief Summary
-----------------
Medical data that contain facial images are particularly sensitive as they retain important personal biometric identity, privacy protection. We developed a novel technology called Digital Mask (DM), based on real-time three-dimensional (3D) reconstruction and deep learning algorithm, to extract disease-relevant features but remove patient identifiable features from facial images of patients.

Official Title
-----------------
Using a Reconstruction Technology With Facial Pathological Features to Auxiliary Diagnosis and Guarantee Patient Privacy

Conditions
-----------------
3D-reconstruction, Patient Privacy, Deep Learning, Digital Medicine

Intervention / Treatment
-----------------
* Diagnostic Test: DM


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The quality of facial images should be clinically acceptable.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| facial videos dataset<br>facial videos collected from Zhongshan Ophthalmic Center of Sun Yat-sen University. | Diagnostic Test: DM<br>* A new technology based on 3D reconstruction and deep learning algorithm to irreversibly erase the biometric attributes whilst retaining the clinical attributes needed for diagnosis and management<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic consistency | For each eye, both the diagnosis from the original videos and the diagnosis from the DM-reconstructed videos were recorded and compared. If the two diagnoses were consistent, it suggests that the reconstruction would be precise enough in clinical practice. | baseline |
Study of ARQ 197 in Hepatocellular Carcinoma (HCC)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and tolerability of ARQ 197 in hepatocellular carcinoma (HCC) patients treated with daily oral ARQ 197, to determine the recommended dose of ARQ 197 in advanced HCC patients.

Official Title
-----------------
Phase I Study of ARQ 197 in Advanced Hepatocellular Carcinoma

Conditions
-----------------
Advanced Hepatocellular Carcinoma

Intervention / Treatment
-----------------
* Drug: ARQ 197


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed HCC patients who are resistant to, intolerable to, or rejecting a systemic sorafenib therapy Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Child-Pugh classification A at the time of registration Adequate bone marrow, liver, and renal functions within 14 days prior to registration Exclusion Criteria: Prior therapy with a c-Met inhibitor (including ARQ 197) Any systemic anti-tumor treatment or investigational agent within 2 weeks prior to registration. If the treatment/agent was antibody, within 4 weeks Local treatment for malignancy within 4 weeks prior to registration Major surgical procedure within 4 weeks prior to registration

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ARQ 197<br> | Drug: ARQ 197<br>* Daily repeating dose of oral ARQ 197, twice a day just after meals. Dose of ARQ 197 will be escalated according to 3+3 rule.<br>* Other names: Tivantinib;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with dose-limiting toxicity (DLT), as a measure of safety and tolerability | Adverse Event collection and assessment will be done for all treated subjects to assess the safety, tolerability. The grading for the severity of the adverse events will be determined according to CTCAE ver 4.0. | DLT observation period will be the first 28 days after the start of ARQ 197 treatment. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Profiles of Pharmacokinetics | maximum concentration (Cmax), area under the curve (AUC), half-life (t1/2), apparent clearance (Cl/F), and apparent volume of distribution in the terminal elimination phase (Vz/F). | Plasma sample correction at pre-dose 1, 2, 4, 6, 10, 12 and 24 hours on day 1; at pre-dose, 1, 2, 4, 6, 10, 12 hours on day 15; and at pre-dose on day 29. | 
| Antitumor effects according to RECIST 1.1. |  | Every 6 weeks |
Drug-free Without Toothache. A Study of Free Dental Treatment as a Part of Substance Abuse Treatment

Study Overview
=================
Brief Summary
-----------------
Objectives: The main objective of the study is to investigate How many patients will attend and complete dental care if they are offered it for free during the stay at The department of substance abuse treatment, University Hospital North Norway (UNN) in Narvik. Explore whether a parallel dental treatment in addition to the other treatment at the department has a beneficial effect on the abuse treatment, or whether it can be disruptive to offer dental treatment in combination with admission for drug rehabilitation?

Detailed Description
-----------------
This is a non-randomized clinical study without a control group. Approximately 50 persons admitted to The department of substance abuse treatment (Russeksjon UNN Narvik) will be offered free dental service during treatment for drug addiction.

Official Title
-----------------
Drug-free Without Toothache. A Non-randomized Intervention Study of Free Dental Treatment as a Part of Substance Abuse Treatment.

Conditions
-----------------
Substance Abuse, Dental Caries

Intervention / Treatment
-----------------
* Procedure: Dental care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: People who are hospitalized for drug abuse at Russeksjon UNN Narvik. Exclusion Criteria: Non

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dental treatment<br>All participants will be offered dental treatment for free. | Procedure: Dental care<br>* Participants will be offered free dental care<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dental treatment | Proportion of participant who attend and complete dental treatment during the hospital stay. | Approximately 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Probability measures | Measurement of drop-out from dental treatment. Which factors increase the success of dental treatment (we do not know which factors this will be. This is an exploratory analysis. | Approximately 12 weeks | 
| Aspects of dental treatment | Will dental treatment have positive or negative impact on drug abuse treatment | Approximately 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non Randomized Interventional study
Effects of Pectin Supplementation in Diarrhea-predominant Irritable Bowel Syndrome

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the effect of pectin, a kind of soluble dietary fiber, on clinical symptoms, gut microbiota and the immune status in patients with diarrhea-predominant irritable bowel syndrome

Detailed Description
-----------------
Patients were randomized to receive either pectin or placebo. Treatment consisted of 6 weeks supplementation with pectin (fiber group) or placebo (maltodextrin). We evaluated the clinical symptoms, gut microbiota and the immune markers in two groups.

Official Title
-----------------
Therapeutic Effects of Pectin Supplementation in Patients With Diarrhea-predominant Irritable Bowel Syndrome

Conditions
-----------------
Irritable Bowel Syndrome

Intervention / Treatment
-----------------
* Dietary Supplement: Pectin
* Dietary Supplement: maltodextrin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients(age≧18y) Admitted for diarrhea-predominant irritable bowel syndrome Exclusion Criteria: Mental disorders Cancer Inflammatory bowel disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: pectin<br>a kind of soluble dietary fiber | Dietary Supplement: Pectin<br>* Pectin （Andeli Ltd. Yantai, China）, 24g/d for six weeks<br>|
| Placebo Comparator: Placebo<br>maltodextrin | Dietary Supplement: maltodextrin<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| efficacy: change of stool frequency, faecal form and clinical symptoms score | change from baseline in stool frequency, faecal form (Bristol stool scale) and clinical symptoms score (7-point Likert scale) at six weeks | six weeks after inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| efficacy: gut microbiota | real-time PCR | six weeks after inclusion | 
| efficacy: cytokine ratios | Cytokine production | six weeks after inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Irritable bowel syndrome, Gut microbiota, Soluble dietary fiber
Main Pancreatic Duct Diameter

Study Overview
=================
Brief Summary
-----------------
The maximal diameter of the pancreatic duct will be measured by endoscopic ultrasound at four different parts: Pancreatic head Pancreatic neck Pancreatic body Pancreatic tail

Detailed Description
-----------------
All patients without pancreatic or biliary disorders undergoing upper-GI endoscopic ultrasound (EUS) are eligible for the study. The maximal diameter of the pancreatic duct will be measured by endoscopic ultrasound in millimeters at four different parts: Pancreatic head Pancreatic neck Pancreatic body Pancreatic tail

Official Title
-----------------
Normal Values of Main Pancreatic Duct Diameter

Conditions
-----------------
Pancreatic Duct Dilatation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Patients undergoing EUS for investigation of non-pancratic disease (e.g. subeptithelial tumor of the upper GI-tract Indication for EUS is undependent from the study Written informed consent Age ≥18 years Exclusion Criteria: Pancreatic diseases (chronic or acute pancreatitis, pancreatic tumor, pancreatic cyst, etc.) Disorders of papilla duodeni major/minor (adenoma/carcinoma of papilla duodeni major or minor) Biliary disorders (bile duct stones, cholangio carcinoma, cholangitis) Elevated Bilirubin and/or Lipase

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximal diameter of main pancreatic duct in millimeters | Measurements of main pancreatic duct at different sections of the pancreas | The measurement is performed once during endosonography. |